The initial public offering for Tarsus Pharmaceuticals has closed, bringing in about $101.2 million, according to a press release.
The IPO consisted of 6,325,000 shares of common stock at a price of $16 per share. This includes 825,000 shares sold upon the full exercise of the underwriters’ option to purchase additional shares of common stock, the release said.
The shares entered the Nasdaq Global Select Market on Oct. 16 under TARS.
Uncategorized